JP2022508699A5 - - Google Patents

Info

Publication number
JP2022508699A5
JP2022508699A5 JP2021545267A JP2021545267A JP2022508699A5 JP 2022508699 A5 JP2022508699 A5 JP 2022508699A5 JP 2021545267 A JP2021545267 A JP 2021545267A JP 2021545267 A JP2021545267 A JP 2021545267A JP 2022508699 A5 JP2022508699 A5 JP 2022508699A5
Authority
JP
Japan
Prior art keywords
radiolabeled compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
mammalian species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508699A (ja
JP7367038B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056033 external-priority patent/WO2020081410A2/en
Publication of JP2022508699A publication Critical patent/JP2022508699A/ja
Publication of JP2022508699A5 publication Critical patent/JP2022508699A5/ja
Application granted granted Critical
Publication of JP7367038B2 publication Critical patent/JP7367038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545267A 2018-10-15 2019-10-14 Lpa1受容体のイメージングのための放射性リガンド Active JP7367038B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862745524P 2018-10-15 2018-10-15
US62/745,524 2018-10-15
PCT/US2019/056033 WO2020081410A2 (en) 2018-10-15 2019-10-14 Radioligands for imaging the lpa1 receptor

Publications (3)

Publication Number Publication Date
JP2022508699A JP2022508699A (ja) 2022-01-19
JP2022508699A5 true JP2022508699A5 (enExample) 2022-08-30
JP7367038B2 JP7367038B2 (ja) 2023-10-23

Family

ID=70284132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021545267A Active JP7367038B2 (ja) 2018-10-15 2019-10-14 Lpa1受容体のイメージングのための放射性リガンド

Country Status (10)

Country Link
US (3) US20210379210A1 (enExample)
EP (1) EP3866692B1 (enExample)
JP (1) JP7367038B2 (enExample)
KR (1) KR102923704B1 (enExample)
CN (1) CN113260310A (enExample)
AU (1) AU2019362770B2 (enExample)
CA (1) CA3116129A1 (enExample)
ES (1) ES3037591T3 (enExample)
SG (1) SG11202103731QA (enExample)
WO (1) WO2020081410A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434655A (zh) 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2025051267A1 (zh) * 2023-09-08 2025-03-13 西藏海思科制药有限公司 一种lpar1拮抗剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2405655T3 (es) 2006-12-26 2013-05-31 Lantheus Medical Imaging, Inc. N-[3-bromo-4-(3-[18F]fluoropropoxi)-bencil]-guanidina para la formación de imágenes de la inervación cardíaca
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
GB201203793D0 (en) 2012-03-05 2012-04-18 Ge Healthcare Ltd Imaging neural activity
US9987381B2 (en) * 2013-10-31 2018-06-05 Bristol-Myers Squibb Company Radioligands for imaging the LPA-1 receptor
US10994033B2 (en) * 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN111712492B (zh) * 2017-12-19 2024-05-31 百时美施贵宝公司 作为lpa拮抗剂的环己基酸三唑唑类
ES2898364T3 (es) * 2017-12-19 2022-03-07 Bristol Myers Squibb Co Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA

Similar Documents

Publication Publication Date Title
JP2022508699A5 (enExample)
JP2019520328A5 (enExample)
JP6682273B2 (ja) 神経細胞イメージング及び治療
JP2019527225A5 (enExample)
AU2014248001A1 (en) Drug combinations to treat cancer
LeBlanc et al. PET and SPECT imaging in veterinary medicine
US10259781B2 (en) Imaging agents
JP7679000B2 (ja) 新規化合物
CN109789227A (zh) 用于癌症成像和疗法的放射性磷脂金属螯合物
Nakata et al. Comparative evaluation of [18F] DiFA and its analogs as novel hypoxia positron emission tomography and [18F] FMISO as the standard
JP2020500884A (ja) イメージング剤および使用の方法
JP7036543B2 (ja) 腫瘍イメージング剤、及びホウ素中性子捕捉療法用腫瘍治療剤
JP6321191B2 (ja) 腎イメージング剤
JP2016511754A (ja) 放射性標識キナゾリン誘導体
US9205156B2 (en) Molecular imaging agents
de Vries et al. Positron emission tomography: measurement of transgene expression
KR102759239B1 (ko) 암 진단에서 방사성표지된 프로가스트린
Wu et al. Ferret thoracic anatomy by 2-deoxy-2-(18F) fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (18F-FDG PET/CT) imaging
KR20190016971A (ko) 심질환의 비침습적 화상 진단제
Yoo et al. Monitoring of macrophage accumulation in statin-treated atherosclerotic mouse model using sodium iodide symporter imaging system
JP7688339B2 (ja) 新規化合物、およびその利用
EP3569589A1 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
AU2010258599B2 (en) PET imaging of fibrogenesis
Watanabe et al. Comparison of multimodal imaging of antisense oligonucleotides (ASOs): PET, SPECT, cryo-fluorescence tomography (CFT), and ARG of mice co-injected with 89Zr, 125I or IR750-labeled ASO
US20200123104A1 (en) Pharmaceutical agent that binds the p2x7 receptor